Abstracts tagged "nanomedicine and rheumatoid arthritis (RA)"

Abstract Number: 2362 • 2014 ACR/ARHP Annual Meeting
Enhanced Efficacy of Dexamethose with Synovial Fibroblast Targeted Micelles in a Collagen-Induced Arthritis Mouse Model
Rebecca A. Bader, David R. Wilson, Arundhati Ramani and Patricia R. Wardwell, Biomedical & Chemical Engineering, Syracuse University, Syracuse, NY
Background/Purpose: A number of conventional, disease modifying anti-rheumatic drugs (DMARDs) are associated with severe side effects due to non-specific targeting and impaired immune function. To…
Abstract Number: 2229 • 2013 ACR/ARHP Annual Meeting
Alleviation Of Collagen-Induced Arthritis By Multifunctional Nanoparticle Containing Methotrexate
You-Jung Ha¹, Sun-Mi Lee², Ji-Hee Lim¹, Hyung-Joon Kim², Sang-Won Lee³, Soo Kon Lee⁴, Kyung-Hwa Yoo² and Yong-Beom Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ²Nanomedical Graduate Program, Department of Physics, Yonsei University, Seoul, South Korea, ³Department of Internal Medicine, Yonsei University College of Medicine, Seoul, NV, South Korea, ⁴Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ⁵Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Methotrexate (MTX) is the most widely used disease-modifying anti-rheumatic drugs for the treatment of rheumatoid arthritis (RA). Despite of its efficacy, the continuous use…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].